ID   BV-173
AC   CVCL_0181
SY   BV173
DR   BTO; BTO:0004950
DR   CLO; CLO_0002052
DR   EFO; EFO_0002118
DR   MCCL; MCC:0000072
DR   CLDB; cl510
DR   CLDB; cl4968
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473373
DR   BioSample; SAMN10988488
DR   CCLE; BV173_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CCTCC; GDC0607
DR   Cell_Model_Passport; SIDM00962
DR   ChEMBL-Cells; CHEMBL3308228
DR   ChEMBL-Targets; CHEMBL2366145
DR   CLS; 300133/p1775_BV-173
DR   Cosmic; 798672
DR   Cosmic; 910710
DR   Cosmic; 922164
DR   Cosmic; 994184
DR   Cosmic; 996292
DR   Cosmic; 998702
DR   Cosmic; 999741
DR   Cosmic; 1019833
DR   Cosmic; 1026570
DR   Cosmic; 1037734
DR   Cosmic; 1070701
DR   Cosmic; 1071881
DR   Cosmic; 1127249
DR   Cosmic; 1176600
DR   Cosmic; 1191703
DR   Cosmic; 1524792
DR   Cosmic-CLP; 910710
DR   DepMap; ACH-000432
DR   DSMZ; ACC-20
DR   GDSC; 910710
DR   GEO; GSM236779
DR   GEO; GSM236815
DR   GEO; GSM886895
DR   GEO; GSM887960
DR   GEO; GSM1374414
DR   GEO; GSM1669633
DR   ICLC; HTL99018
DR   IGRhCellID; BV173
DR   LiGeA; CCLE_631
DR   LINCS_LDP; LCL-1111
DR   Lonza; 117
DR   PharmacoDB; BV173_148_2019
DR   Wikidata; Q54798653
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1720549;
RX   PubMed=3098690;
RX   PubMed=3332852;
RX   PubMed=3856862;
RX   PubMed=6572735;
RX   PubMed=9680106;
RX   PubMed=14504097;
RX   PubMed=16523483;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: 30-35 hours (PubMed=6572735); ~48 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: BCR-ABL1 gene fusion.
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.38%; Native American=0%; East Asian, North=2.14%; East Asian, South=0%; South Asian=2.51%; European, North=52.2%; European, South=41.77% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): CLS; Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,10
ST   D16S539: 11,13
ST   D18S51: 12,16
ST   D21S11: 30,32
ST   D3S1358: 16,17
ST   D5S818: 10,12
ST   D7S820: 10,11
ST   D8S1179: 11,12,13
ST   FGA: 20,24
ST   Penta D: 11
ST   Penta E: 12,16
ST   TH01: 6,9.3
ST   TPOX: 8,10
ST   vWA: 16
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 31
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1720549; DOI=10.1073/pnas.88.23.10735;
RA   Ziemin-van der Poel S., McCabe N.R., Gill H.J., Espinosa R. III,
RA   Patel Y., Harden A., Rubinelli P., Smith S.D., Le Beau M.M.,
RA   Rowley J.D., Diaz M.O.;
RT   "Identification of a gene, MLL, that spans the breakpoint in 11q23
RT   translocations associated with human leukemias.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10735-10739(1991).
//
RX   PubMed=3098690; DOI=10.1002/ijc.2910390116;
RA   Th'ng K.H., Garewal G., Kearney L., Rassool F., Melo J.V., White H.,
RA   Catovsky D., Foroni L., Luzzatto L., Goldman J.M.;
RT   "Establishment and characterization of three new malignant lymphoid
RT   cell lines.";
RL   Int. J. Cancer 39:89-93(1987).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=3856862; DOI=10.1073/pnas.82.6.1810;
RA   Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.;
RT   "Cell lines and clinical isolates derived from Ph1-positive chronic
RT   myelogenous leukemia patients express c-abl proteins with a common
RT   structural alteration.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985).
//
RX   PubMed=6572735;
RA   Pegoraro L., Matera L., Ritz J., Levis A., Palumbo A., Biagini G.;
RT   "Establishment of a Ph1-positive human cell line (BV173).";
RL   J. Natl. Cancer Inst. 70:447-453(1983).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=16523483; DOI=10.1002/gcc.20317;
RA   Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H.,
RA   Dexter T., Ashworth A., Kearney L.;
RT   "Array CGH of fusion gene-positive leukemia-derived cell lines reveals
RT   cryptic regions of genomic gain and loss.";
RL   Genes Chromosomes Cancer 45:554-564(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//